BridgeBio Pharma (BBIO) Cash & Current Investments (2018 - 2026)

BridgeBio Pharma has reported Cash & Current Investments for 9 years, with the latest figure at $940.2 million in Q1 2026.

• Quarterly Cash & Current Investments rose 73.92% year-over-year to $940.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $940.2 million (up 73.92% YoY) and the FY2025 annual result came in at $587.5 million, up 63.29% from the prior year.
• Cash & Current Investments improved to $940.2 million in Q1 2026 per BBIO's latest filing, from $587.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $940.2 million in Q1 2026 and troughed at $266.3 million in Q3 2024.
• A 5-year average of $487.5 million and a median of $475.4 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments slumped 55.47% in 2022, then soared 73.92% in 2026.
• Over 5 years, Cash & Current Investments stood at $414.6 million in 2022, then declined by 5.31% to $392.6 million in 2023, then retreated by 8.36% to $359.8 million in 2024, then surged by 63.29% to $587.5 million in 2025, then soared by 60.04% to $940.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $940.2 million, $587.5 million, and $286.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.